<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161466">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924195</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-03-II</org_study_id>
    <nct_id>NCT01924195</nct_id>
  </id_info>
  <brief_title>Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818)Hydrochloric Capsule as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug
      Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
      multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance
      to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of
      andvanced non-small cell lung cancer who failed two lines of chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>enhanced CT/MRI scan</measure>
    <time_frame>each 42 days up to disease progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles. Refer to recist 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>each 21 days up to intolerance the toxicity(or PD)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>contain Serious Adverse Event To evaluate the safety of Anlotinib by CTC AE 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib hydrochloric capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anlotinib hydrochloric capsule 12mg QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloric capsule</intervention_name>
    <description>Anlotinib hydrochloric capsule 12mg QD po. continue for tow weeks then stop one week</description>
    <arm_group_label>Anlotinib hydrochloric capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Placebo capsule QD po. continue for tow weeks then stop one week</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathology diagnosed with advanced NSCL with measurable lesions;

          2. Have failed for 2 lines of chemotherapy;

          3. 18-70years,ECOG PS:0-2,Life expectancy of more than 3 months;

          4. Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks;

          5. main organs function is normal;

          6. must be agreed to take contraceptive measures during the study and within 6 months
             after end.

        Exclusion Criteria:

          1. SCLC(including mixed with NSCLC);

          2. the central cavity of Squamous cell carcinoma and hemoptysis with NSCLC;

          3. patients failed to use the anti-tumor angiogenesis therapy;

          4. patients has many influence factors toward oral medications ;

          5. Brain metastases patients accompanied by symptoms or symptom control for less than
             two months;

          6. patients with severe and failed to controlled diseases,including: suboptimal blood
             pressure control;suffering from myocardial ischemia or above grade I myocardial
             infarction, arrhythmias and Class I heart failure;activity or failure to control
             severe infections;liver disease such as cirrhosis, decompensated liver disease,
             chronic active hepatitis;poorly controlled diabetes (FBG)&gt;10mmol/L);urine
             protein≥++,etc.

          7. patients failed to heal wounds or fractures for Long-term;

          8. 4 weeks before enrollment, patients appeared NCI CTC AE grading &gt;1 pulmonary
             hemorrhage; 4 weeks before enrollment, patients who  appeared NCI CTC AE grade&gt; 2
             have other parts of the bleeding; patients has a tendency to bleed (eg active peptic
             ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin,
             heparin or its analogues;

          9. patients occurred venous thromboembolic events within 6 months;

         10. patients has HIV-positive or organ transplantation;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bao hui Han, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chest hospital affiliated to Shanghai jiaotong university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bao hui Han, Professor</last_name>
    <email>xkyyhan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan kai Shi, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Hong yu Wang, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing chest hospital，capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bao lan Li, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Ying Hu, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoming Wu, Doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Kexiong Lin, Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Guoming Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kexiong Lin, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Province Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Luo, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yi Luo, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianan Huang, doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Junhong Jiang, doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jianan Huang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin province tumor hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Xian hong Liu, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Province Tumor Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhehai Wang, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhehai Wang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chest hospital affiliated to Shanghai jiaotong university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bao hui Han, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhi qiang Gao, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Li, doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Yiping Han, doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Qiang Li, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiping Han, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>You Lu, doctor</last_name>
    </contact>
    <contact_backup>
      <last_name>Li Ren, doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>You Lu, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Ren, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Li, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Kai Li, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital,zhejiang university</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian ying Zhou, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhi jie Pan, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiping Zhang, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yiping Zhang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 5, 2013</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung</keyword>
  <keyword>Anlotinib</keyword>
  <keyword>AL3818</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
